About Protein FAM13C
Protein FAM13C (FAM13C) is a protein
from Homo sapiens identified by UniProt accession
Q8NE31, 585 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | Protein FAM13C |
| UniProt accession | Q8NE31 |
| Gene | FAM13C |
| Organism | Homo sapiens |
| Length | 585 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (39)
Diseases linked to this target (Open Targets).
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- metabolite measurement · score 0.08
- hemoglobin measurement · score 0.08
- DNA methylation · score 0.05
- triglyceride measurement · score 0.05
- urate measurement · score 0.05
- body height · score 0.05
- vital capacity · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NE31-F1 | alphafold | PREDICTED | 60.51 | — |
Amino-acid sequence (585 residues)
MFSCFCFSLQ DNSFSSTTVT ECDEDPVSLH EDQTDCSSLR DENNKENYPD AGALVEEHAP PSWEPQQQNV EATVLVDSVL RPSMGNFKSR KPKSIFKAES GRSHGESQET EHVVSSQSEC QVRAGTPAHE SPQNNAFKCQ ETVRLQPRID QRTAISPKDA FETRQDLNEE EAAQVHGVKD PAPASTQSVL ADGTDSADPS PVHKDGQNEA DSAPEDLHSV GTSRLLYHIT DGDNPLLSPR CSIFSQSQRF NLDPESAPSP PSTQQFMMPR SSSRCSCGDG KEPQTITQLT KHIQSLKRKI RKFEEKFEQE KKYRPSHGDK TSNPEVLKWM NDLAKGRKQL KELKLKLSEE QGSAPKGPPR NLLCEQPTVP RENGKPEAAG PEPSSSGEET PDAALTCLKE RREQLPPQED SKVTKQDKNL IKPLYDRYRI IKQILSTPSL IPTIQEEEDS DEDRPQGSQQ PSLADPASHL PVGDHLTYSN ETEPVRALLP DEKKEVKPPA LSMSNLHEAT MPVLLDHLRE TRADKKRLRK ALREFEEQFF KQTGRSPQKE DRIPMADEYY EYKHIKAKLR LLEVLISKQD VAKTI
Explore Protein FAM13C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets